Literature DB >> 26108445

Topical combination therapy with vitamin D3 and corticosteroid ointment for palmoplantar pustulosis: A prospective, randomized, left-right comparison study.

Mayuko Muro1, Hiroshi Kawakami1, Yuka Matsumoto1, Namiko Abe1, Ryoji Tsuboi1, Yukari Okubo1.   

Abstract

BACKGROUND: Vitamin D3 ointment and corticosteroid ointment are both used for the treatment of palmoplantar pustulosis (PPP). However, to date there is no systematic study of the efficacy of combination therapy for the treatment of PPP.
OBJECTIVE: We compared the efficacy of a topical combination therapy with vitamin D3 and a topical corticosteroid with that of topical corticosteroid alone in the treatment of PPP.
METHOD: We evaluated left-right comparison study of the efficacy of a combination therapy consisting of maxacalcitol ointment and betamethasone butyrate propionate ointment (BBP), and monotherapy with BBP alone in 27 patients with PPP for 8 weeks.
RESULTS: The improvement in the symptom (erythema, pustules/vesicles, hyperkeratosis/scales) scores was high for the combination therapy. In particular, the improvement rate for pustules/vesicles at week 8 after the combination therapy was significantly higher than for the monotherapy (p < 0.05).
CONCLUSION: This combination regimen demonstrated that not only topical corticosteroids, but also topical vitamin D3 ointment, is useful for the treatment of PPP.

Entities:  

Keywords:  Betamethasone butyrate propionate ointment; maxacalcitol ointment; palmoplantar pustulosis

Mesh:

Substances:

Year:  2015        PMID: 26108445     DOI: 10.3109/09546634.2015.1052036

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  8 in total

Review 1.  [Pustular psoriasis].

Authors:  P Weisenseel; D Wilsmann-Theis; C Kahl; K Reich; R Mössner
Journal:  Hautarzt       Date:  2016-06       Impact factor: 0.751

2.  Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.

Authors:  Tadashi Terui; Satomi Kobayashi; Yukari Okubo; Masamoto Murakami; Keiichiro Hirose; Hiroshi Kubo
Journal:  JAMA Dermatol       Date:  2018-03-01       Impact factor: 10.282

Review 3.  Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments.

Authors:  Magdalena Misiak-Galazka; Joanna Zozula; Lidia Rudnicka
Journal:  Am J Clin Dermatol       Date:  2020-06       Impact factor: 7.403

4.  Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.

Authors:  Yukari Okubo; Hitomi Morishima; Richuan Zheng; Tadashi Terui
Journal:  J Dermatol       Date:  2021-08-28       Impact factor: 3.468

Review 5.  Involvement of Molecular Mechanisms between T/B Cells and IL-23: From Palmoplantar Pustulosis to Autoimmune Diseases.

Authors:  Takemichi Fukasawa; Asako Yoshizaki-Ogawa; Atsushi Enomoto; Kiyoshi Miyagawa; Shinichi Sato; Ayumi Yoshizaki
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

6.  Interventions for chronic palmoplantar pustulosis.

Authors:  Grace Obeid; Giao Do; Lisa Kirby; Carolyn Hughes; Emilie Sbidian; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2020-01-20

Review 7.  Glucocorticoids in Sepsis: To Be or Not to Be.

Authors:  Jolien Vandewalle; Claude Libert
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

Review 8.  Pustular Psoriasis: From Pathophysiology to Treatment.

Authors:  Giovanni Genovese; Chiara Moltrasio; Nicoletta Cassano; Carlo Alberto Maronese; Gino Antonio Vena; Angelo Valerio Marzano
Journal:  Biomedicines       Date:  2021-11-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.